Supplementary Figure 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

Supplementary Figure 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial

<p>Supplementary Figure 2 shows the distribution of individual total (combined adenomatous and serrated polyp) colorectal polyp counts according to seAFOod trial treatment allocation by factorial margins and ALOX SNP genotypes.</p>

Guardat en:
Dades bibliogràfiques
Autor principal: John R. Davies (17314989) (author)
Altres autors: Tracey Mell (17314992) (author), Harriett Fuller (17314995) (author), Mark Harland (17314998) (author), Rasha N.M. Saleh (17315001) (author), Amanda D. Race (17315004) (author), Colin J. Rees (17315007) (author), Louise C. Brown (17315010) (author), Paul M. Loadman (17315013) (author), Amy Downing (17315016) (author), Anne Marie Minihane (17315019) (author), Elizabeth A. Williams (17315022) (author), Mark A. Hull (17315025) (author)
Publicat: 2025
Matèries:
Cancer
Clinical Research and Trials
Cancer Prevention
Clinical prevention studies
Pre-neoplasia
Clinical Trial Results
Phase III clinical trials
Gastrointestinal Cancers
Colorectal cancer
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars